

PRESS RELEASE

BioMarker Pharmaceuticals Evaluates Combination Herbal Formulation for Lowering Cholesterol and Improving Heart Health

San Jose, Calif., December 24, 2006 - BioMarker Pharmaceuticals, Inc. launched the first rigorous clinical study of BM-A1, a proprietary combination herbal formulation designed to promote heart health by lowering plasma cholesterol and triglycerides. BioMarker Pharmaceuticals is a privately held company focused on developing and manufacturing science-based pharmaceuticals, nutraceuticals, and diagnostics for the treatment and prevention of age-related disorders.

BM-A1 has been formulated from botanicals used in traditional Chinese medicine. BioMarker has an arrangement to obtain plant extracts from the original areas in China where the plants are grown and harvested. The specific plants comprising the BM-A1 formulation have been shown individually and in combination to contain bioactive chemicals that affect lipid metabolism. Studies have been conducted in vitro and in animals, and preliminary efficacy of BM-A1's ability to lower plasma cholesterol and triglyceride levels has been obtained in humans. Based on these promising results, BioMarker is conducting a randomized, double-blind, placebo-controlled clinical trial of BM-A1 for the reduction of hyperlipidemia in subjects with low to moderate cardiovascular risk.

"Medicus Research is pleased to be working with BioMarker Pharmaceuticals to conduct this clinical evaluation of the safety and efficacy of BM-A1" said Dr. Jay Udani M.D., the CEO and Medical Director of Medicus Research and Medical Director of the Northridge Hospital Integrative Medicine Program, Northridge, CA,. "The guidelines of the National Cholesterol Education Program recommend changes in diet and lifestyle as first steps towards cholesterol reduction before individuals begin a pharmaceutical intervention. Natural products which are clinically validated for reducing risk of cardiovascular disease can play an important role in this diet and lifestyle modification."

BM-A1 is a proprietary formulation containing concentrated extracts of green tea, ginkgo biloba and grape seed. These medicinal plants have been widely studied for many therapeutic indications however few studies have met the "gold standard" of scientific investigation used to design this clinical trial. This will be the first rigorous scientific evaluation of the combination herbal formulation in humans.

"BioMarker Pharmaceuticals is committed to the discovery and development of science-based therapeutic products that are designed to promote healthy aging" said Dr. Xi Zhao-Wilson, CEO & President of BioMarker Pharmaceuticals Inc. "BM-A1 will provide individuals a natural product alternative to pharmaceutical interventions for lowering cholesterol and triglycerides, both major risk factors for cardiovascular disease. This study is designed to provide a clear determination of the safety and efficacy of BM-A1 in humans and is an outgrowth of the extensive in vitro and animal testing that BioMarker has conducted or supported in advancing this innovative product".

If proven free of risks and side effects, as well as effective in reducing the symptoms of hyperlipidemia, the BM-A1 combination herbal formulation could offer individuals a number of advantages over conventional pharmacotherapy.

About BioMarker Pharmaceuticals, Inc.

BioMarker Pharmaceuticals, Inc. is a leading developer and manufacturer of science-based nutraceuticals and therapeutics designed to treat and prevent the chronic disorders associated with aging. Longevity therapeutics have the potential for greatly extending a normal and healthy lifespan. The company's products are based on activating the genes and proteins responsible for increased longevity in the only scientifically proven model that shows increased lifespan results from a severe reduction in calories (caloric restriction). BioMarker uses advanced DNA-based technology to identify interventions that can substitute for and mimic the effects of caloric restriction. The company, headquartered in San Jose, Calif., holds worldwide, exclusive licenses to patents for identifying calorie restriction mimetics. For more information about BioMarker Pharmaceuticals, Inc., please visit the company's Web site at www.biomarkerinc.com.

FOR FURTHER INFORMATION: Paul Watkins, VP of Business Development
BioMarker Pharmaceuticals, Inc.
5941 Optical Court
San Jose, CA 95008
Tel: 408-257-2000
Fax: 408-356-6661
Email: press@biomarkerinc.com